RxDoctor Payments Data

Curtis Crylen, MD

Urology · Greeley, CONPI 1881644532

Payments from drug & device makers

$712in general payments, 2019–2025

Across 20 payments — averaging $35.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$373
  • Myovant Sciences Inc.$266
  • Astellas Pharma US Inc$30
  • Intuitive Surgical$17
  • Boston Scientific$15
  • Pfizer$12

What the payments were for

  • Travel & lodging$25836%
  • Food & beverage$37052%
  • Education$8312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$712 in reported general payments places this provider in the 20th percentile of 225 urology providers in Colorado.

See all urology providers in Colorado

Medicare billing

Part B allowed, 2024
$139,172
Medicare patients
383
Services billed
1,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide12$176,289
MyrbetriqMirabegron111$84,207
Tamsulosin Hcl544$8,071
Testosterone28$5,180
Potassium Citrate ErPotassium Citrate42$4,605
Finasteride351$4,596
Oxybutynin Chloride ErOxybutynin Chloride250$3,609
NitrofurantoinNitrofurantoin Macrocrystal48$2,565
Testosterone Cypionate39$1,808
Dutasteride29$1,486
Estradiol16$1,252
Fesoterodine Fumarate ErFesoterodine Fumarate16$1,138
Solifenacin Succinate23$730
Cephalexin74$693
Oxybutynin Chloride29$688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$30$260,496123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 225 urology providers in Colorado.

Other urology in Greeley

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →